Where is Eli Lilly headquartered?

Eli Lilly's world headquarters is the Lilly Corporate Center at 893 S Delaware Street, Indianapolis, IN 46225. The campus is a landmark of downtown Indianapolis, spanning millions of square feet and housing the company's global C-suite, key R&D leadership coordination, corporate functions (legal, finance, HR, IT), and regulatory affairs. The adjacent Lilly Technology Center at 1200 W. Morris Street handles manufacturing IT and process automation for the Indianapolis production campus.

Indianapolis is the operational nerve center of Lilly's global operations. The majority of Executive Committee members are based here, including David Ricks (CEO), Lucas Montarce (CFO), and Diogo Rau (CIDO). Lilly is by far the largest private-sector employer in Indianapolis — with roughly 23,500 US employees concentrated in the metro area — and a cornerstone of Indiana's economy and life sciences ecosystem. The company has invested billions in new Indianapolis-area manufacturing capacity since 2023 to meet GLP-1 demand, reinforcing Indiana's position as the center of tirzepatide's global supply chain.

Lilly's second-largest US scientific hub is the Lilly Biotechnology Center in San Diego, California (10290 Campus Point Drive), which focuses on biologics and biotech R&D including antibody engineering, immuno-oncology, and next-generation drug modalities. The company maintains a Washington, DC government affairs office (555 12th Street NW) given its significant exposure to US drug pricing policy — Mounjaro and Zepbound are among the highest-profile drugs targeted by IRA Medicare price negotiations and White House drug pricing executive actions.

Globally, Lilly operates API (active pharmaceutical ingredient) and drug product manufacturing sites in Cork/Kinsale, Ireland; Branchburg, NJ; Research Triangle Park, NC; Fegersheim, France; and Shropshire, UK — among others. Commercial offices span more than 18 countries including India (Gurgaon), China (Shanghai), Japan, Germany, and Brazil. The company aggressively expanded manufacturing capacity in 2023–2025 to meet GLP-1 demand, with major new investments in Indiana and internationally. The Cork, Ireland site is particularly significant as a large-scale API manufacturing hub for tirzepatide destined for EU markets.

For enterprise sales targeting Lilly, Indianapolis is the mandatory entry point for deals involving C-suite and Executive Committee sign-off. This is where David Ricks (CEO), Lucas Montarce (CFO), Diogo Rau (CIDO), and the division presidents sit. Field events, executive briefings, and executive business center-style engagements belong in Indianapolis, not Chicago or New York — and any vendor claiming to sell enterprise software without an Indianapolis presence is starting at a disadvantage.

For R&D-oriented vendors (clinical data platforms, AI drug discovery, biostatistics tools, CRO services), San Diego is the secondary hub where Lilly's biotechnology center is concentrated. For government affairs, pricing, and reimbursement-related discussions, the Washington DC office is the relevant venue. For manufacturing automation, supply chain software, and GMP compliance tools — Indianapolis manufacturing campuses plus the Cork, Ireland site are the key locations. International selling should prioritize the EU (UK, France, Germany, Ireland) and India/China commercial hubs, which are growing rapidly on Mounjaro's global rollout and expanding access initiatives.